Roxane Laboratories: Your Partner in Growth

Generic SupplementsGeneric Supplement 2012

For your business and the well-being of millions

At Roxane Laboratories, growth means we’re on the path of progress and possibilities for our customers and patients nationwide. We want to ensure they have access to quality, safe, and affordable pharmaceuticals. As we grow our product lines, we know we’re entrusted to further develop the possibilities of generic drugs.

Growth and innovation feed our pipeline to supply customers with a range of medications from our FDA-approved facilities. Roxane’s focus on developing innovative, technically complex products has led to our continual advancements in controlled substances, sustained-release items, potent compounds, unit dose, and bulk packaging.

Roxane’s highly skilled researchers and scientists work to expand the number of generic pharmaceuticals. Our patent-experienced attorneys and purchasing team help put more affordable generic treatments on the market and into your hands sooner. We have developed a lean manufacturing model staffed by a skilled, flexible workforce that allows us to quickly shift production based on customer needs and other business opportunities. As always, we maintain our distinctive levels of safety, quality, and compliance.

As Roxane has continued to grow our product lines to offer a variety of treatment options that meet patients’ changing needs, we’ve also grown our manufacturing facilities. In 2011, we expanded our Columbus Wilson Road facility, adding a 105,000-square-foot complex that, like all our efficient operations, meets rigorous design standards required for safe and compliant manufacturing.

Quality, safe, affordable growth continues for Roxane with the following new generics recently introduced into the marketplace.

Visit to view Roxane's complete Product Catalog, as well as access the TouchPoint Customer Service Center for 24/7 information about your account and order status.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.